Publications

Filter Publications By:

ASLAN001 / Cancer

06/17/2013

Heterocyclic Compounds GRC

Process Research and Development of the Tyrosine Kinase Inhibitor Varlitinib Tosylate (ARRY-543 Ditosylate)

D. D. Hennings, et al.

Filanesib / Multiple Myeloma

06/17/2013

European Hematology Association Annual Congress

ALPHA 1-ACID GLYCOPROTEIN (AAG) IS A POTENTIAL PATIENT SELECTION MARKER FOR CLINICAL ACTIVITY OF ARRY-520 IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM)

B.J. Tunquist, et al.

Filanesib / Multiple Myeloma

06/12/2013

European Hematology Association Annual Congress

Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

J.J. Shah, MD, et al.

Selumetinib / Cancer

06/08/2013

Children’s Tumor Foundation’s Neurofibromatosis Conference

A Phase I Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib) in Children and Young Adults with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibromas (PN)

B. Widemann, MD, et al.

Danoprevir / Hepatitis C

06/05/2013

Journal of Medicinal Chemistry

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

Y. Jiang, et al.

Encorafenib / Cancer

06/03/2013

American Society of Clinical Oncology Annual Meeting

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors

R. Kefford, et al.

Encorafenib / Cancer

06/03/2013

American Society of Clinical Oncology Annual Meeting

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors

R. Kefford, et al.

Selumetinib / Cancer

06/01/2013

American Society of Clinical Oncology Annual Meeting

Phase II Study of Selumetinib vs Temozolomide in Patients with Advanced Uveal Melanoma (CTEP #8443)

R. D. Carvajal

ARRY-502 / Asthma

05/13/2013

American Thoracic Society International Conference

Th2 Signature Selection Strategies for CRTh2 Antagonists: Baseline Characteristics of a Mild to Moderate Persistent Asthma Population

D. Chantry, et al.

ARRY-614 / MDS

04/06/2013

American Association for Cancer Research Annual Meeting

The Design and Early Development of the P38/Tie-2 inhibitor, ARRY-614 in Hematologic Cancers

K. Koch Ph.D.